Orchid Pharma Ltd

Orchid Pharma Ltd share price gained 1.32% to Rs 1047.1. The Company's net profit plunged by 89.61% to Rs 2.58 crore, while revenue from operations reduced 17.42% to Rs 304.17 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.19 lakh crore, rising 4.13%. It has inched up 0.05% over last one week and moving up by 10.53% in last one month while the market capitalization of Orchid Pharma Ltd has marginally improved by 4.23% and 175.63% in the same period respectively. Profit before tax (PBT) of Orchid Pharma Ltd stood at Rs 2.65 crore in Q2 FY26, tumbling by 138.46% year-on-year, and nosediving by 89.34% quarter-on-quarter. EBITDA came in at Rs 12 crore, tanking 170.67% YoY and plunging by 45.65% sequentially. Total expenses fell by 13.74% to Rs 301.12 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 206.42 crore, slightly declining by 1.63% YoY, while employee benefits expense was at Rs 28.04 crore, ticking higher by 1.52% YoY. For the TTM ended FY26, revenue from operations grew 12.52% to Rs 921.93 crore, while net profit grew slightly 0.74% to Rs 95.76 crore, compared to previous TTM. EBITDA soared by 8013% to Rs 89.71 crore, and PBT saw a minor gain of 3.93% to Rs 95.56 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 19.22 crore in FY26, as against Rs 125.99 crore in FY25. Orchid Pharma Ltd surged by 39.91% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 3.21% during the same period.

Orchid Pharma will hold a meeting of the Board of Directors of the Company on 1 August 2026.

Exblifep (cefepime/enmetazobactam), a novel combination antibiotic for the treatment of complicated urinary tract infections (cUTI) and hospital-acquired and ventilator-associated bacterial pneumonia (HAP/VAP) caused by Gram-negative bacterial pathogens, subject to regulatory approval by the Ministry of Health of the Russian Federation. Exblifep is a carbapenem-sparing antibiotic developed to address the growing clinical challenge posed by extended-spectrum beta-lactamase (ESBL)-producing Gram-negative bacteria in serious hospital infections. The product is approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), is included in IDSA and EUCAST treatment guidelines, and is the first new chemical entity originating from an Indian pharmaceutical company to receive both approvals. Under the agreement, Pharmasyntez will hold the exclusive rights to register and commercialize Exblifep in Russia, with Orchid supplying the finished dosage form. The company said the partnership represents a potential opportunity of approximately $178 million over the first 10 years, driven by significant unmet clinical needs and large hospital procurement volumes in the Russian market. Manish Dhanuka, managing director, Orchid Pharma, said, 'Our partnership with Pharmasyntez marks an important step in making Exblifep available to patients in Russia. Pharmasyntez's deep reach into the Russian hospital procurement system makes them the right partner to ensure this medicine gets to the clinicians and patients who need it. Natalia Malykh, vice president of business development at the Pharmasyntez group, said, 'Antimicrobial resistance is one of the most significant challenges facing modern medicine, making the development of new antibiotics critical. Orchid Pharma has met this challenge by developing the novel antibiotic Exblifep (cefepime/enmetazobactam). This licensing agreement with Pharmasyntez enables Russian patients to gain access to modern antibacterial therapy.' Orchid Pharma is a Chennai-based, fully vertically integrated pharmaceutical company with end-toend capabilities from Key Starting Materials (KSMs) to Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs), The company specializes in the development and manufacturing of complex injectable antibiotics. The company reported a 6.68% increase in consolidated net profit to Rs 23.78 crore for the fourth quarter ended March 2026, compared with Rs 22.29 crore in the corresponding quarter last year. Revenue from operations rose marginally to Rs 237.61 crore in Q4 FY26 as against Rs 237.48 crore posted in the same period last year.Powered by Capital Market - Live

Orchid Pharma (Orchid) and Pharmasyntez JSC (Pharmasyntez) have entered into a licensing and supply agreement for Exblifep' (cefepime/enmetazobactam), a novel combination antibiotic for the treatment of complicated urinary tract infections (cUTI) and hospital-acquired and ventilator-associated bacterial pneumonia (HAP/VAP) caused by Gram negative bacterial pathogens, subject to regulatory approval by the Ministry of Health of the Russian Federation. Exblifep is a carbapenem-sparing antibiotic developed to address the growing clinical challenge posed by ESBL-producing Gram-negative bacteria in serious hospital infections. The product is approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), is included in IDSA and EUCAST treatment guidelines, and is the first new chemical entity originating from an Indian pharmaceutical company to receive both approvals. Under the agreement, Pharmasyntez will hold the exclusive rights to register and commercialize Exblifep in Russia, with Orchid supplying the finished dosage form. The partnership represents a potential opportunity of approximately USD 178 million over the first 10 years, reflecting the scale of unmet clinical need and the significant hospital procurement volumes in the Russian market.

Revenue from operations rose marginally to Rs 237.61 crore in Q4 FY26 as against Rs 237.48 crore posted in the same period last year. Profit before exceptional items and tax stood at Rs 22.25 crore, up 16.55% from Rs 19.09 crore reported in Q4 FY25. The company reported exceptional items of Rs 0.54 crore during the quarter. For the full financial year FY26, the company reported a 79.37% decline in consolidated net profit to Rs 20.55 crore, while revenue from operations fell 11.99% year-on-year to Rs 811.33 crore compared with FY25. Orchid Pharma is a Chennai-based pharmaceutical company engaged in the development, manufacture and marketing of bulk actives, formulations and nutraceuticals, with exports to over 40 countries. Powered by Capital Market - Live

Net profit of Orchid Pharma rose 6.68% to Rs 23.78 crore in the quarter ended March 2026 as against Rs 22.29 crore during the previous quarter ended March 2025. Sales rose 0.05% to Rs 237.61 crore in the quarter ended March 2026 as against Rs 237.48 crore during the previous quarter ended March 2025. For the full year,net profit declined 79.38% to Rs 20.55 crore in the year ended March 2026 as against Rs 99.66 crore during the previous year ended March 2025. Sales declined 12.00% to Rs 811.33 crore in the year ended March 2026 as against Rs 921.93 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales237.61237.48 0 811.33921.93 -12 OPM %11.3111.78 -5.0712.71 - PBDT31.1127.97 11 63.04130.11 -52 PBT22.2519.09 17 27.5995.56 -71 NP23.7822.29 7 20.5599.66 -79 Powered by Capital Market - Live

Orchid Pharma will hold a meeting of the Board of Directors of the Company on 25 May 2026.

Net loss of Orchid Pharma reported to Rs 12.61 crore in the quarter ended December 2025 as against net profit of Rs 20.78 crore during the previous quarter ended December 2024. Sales declined 4.63% to Rs 207.27 crore in the quarter ended December 2025 as against Rs 217.34 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales207.27217.34 -5 OPM %0.7512.13 - PBDT3.9931.06 -87 PBT-5.0422.45 PL NP-12.6120.78 PL Powered by Capital Market - Live

Orchid Pharma will hold a meeting of the Board of Directors of the Company on 11 February 2026.Powered by Capital Market - Live

Net loss of Orchid Pharma reported to Rs 5.72 crore in the quarter ended September 2025 as against net profit of Rs 27.24 crore during the previous quarter ended September 2024. Sales declined 13.10% to Rs 193.52 crore in the quarter ended September 2025 as against Rs 222.70 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales193.52222.70 -13 OPM %-0.7613.62 - PBDT5.5734.53 -84 PBT-3.3325.90 PL NP-5.7227.24 PL Powered by Capital Market - Live